Research ArticleATOPY

Blood natural killer cell deficiency reveals an immunotherapy strategy for atopic dermatitis

See allHide authors and affiliations

Science Translational Medicine  26 Feb 2020:
Vol. 12, Issue 532, eaay1005
DOI: 10.1126/scitranslmed.aay1005

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Nurturing NK cells to treat atopic dermatitis

The skin condition atopic dermatitis (AD) is driven by a type 2 immune response. Mack et al. performed high-dimensional immune profiling of patients with AD and revealed deficiencies in certain subsets of natural killer (NK) cells. NK cells showed signs of activation-induced cell death and were restored in patients that responded to immunotherapy. Circulating NK cells were also decreased in a mouse AD model; boosting NK cells with an IL-15 superagonist ameliorated symptoms in the mice. These results suggest that strategies to restore NK cells could help rebalance immunity in AD.

View Full Text

Stay Connected to Science Translational Medicine